about
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several ne...
Read More
220.61
2.07
(0.95%)
4.2M
XNYS Volume
XNYS 26 Sep, 2025 5:30 PM (EDT)
Medium Financial Strength
Mid Valuation
Technically Neutral
Mid-range Performer
These stocks average quality, financial and technical aspects make them being considered by the investor who are not looking for high risk stocks.
View Similar
Embed DVM
AbbVie Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..